Document ID: chunk:federal_register_of_legislation:F2025C00119:clause:3_1:p17
Version: federal_register_of_legislation:F2025C00119
Segment Type: clause
Provision Reference: sch 3 cl 1 (pt 17/69)
Character Range: 301539–311206

be through only one of the two continuing treatment regimens at any given time
C10939              P10939         Atezolizumab                                                                 Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures ‑ Streamlined Authority Code 10939
                                                                                                                Initial treatment
                                                                                                                Patient must be undergoing combination treatment with bevacizumab and atezolizumab until disease progression, unless not tolerated.
                                                                                                                Patient must have a WHO performance status of 0 or 1; AND
                                                                                                                Patient must not be suitable for transarterial chemoembolisation; AND
                                                                                                                Patient must have Child Pugh class A; AND
                                                                                                                The condition must be untreated with systemic therapy; OR
                                                                                                                Patient must have developed intolerance to a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) of a severity necessitating permanent treatment withdrawal.
C10972              P10972         Atezolizumab                                                                 Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures ‑ Streamlined Authority Code 10972
                                                                                                                Continuing treatment where bevacizumab is discontinued ‑ 4 weekly treatment regimen
                                                                                                                Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND
                                                                                                                Patient must not have developed disease progression while being treated with this drug for this condition.
                                                                                                                PBS supply of this drug must be through only one of the two continuing treatment regimens at any given time
C11015              P11015         Obinutuzumab                                                                 Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures ‑ Streamlined Authority Code 11015
                                                                                                                For combination use with venetoclax treatment cycles 1 to 6 inclusive in first‑line therapy
                                                                                                                The condition must be untreated; AND
                                                                                                                The treatment must be in combination with PBS‑subsidised venetoclax.
C11099                             Bortezomib                                                                   Multiple myeloma
C11391              P11391         Ipilimumab                                                                   Stage IV (metastatic) non‑small cell lung cancer (NSCLC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures ‑ Streamlined Authority Code 11391
                                                                                                                Continuing combination treatment (with nivolumab) of first‑line drug therapy
                                                                                                                Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND
                                                                                                                Patient must not have developed disease progression while receiving PBS‑subsidised treatment with this drug for this condition; AND
                                                                                                                The treatment must not exceed 24 months in total, measured from the initial dose, or, must not extend beyond disease progression, whichever comes first; AND
                                                                                                                The treatment must be in combination with nivolumab.
C11468              P11468         Nivolumab                                                                    Stage IV (metastatic) non‑small cell lung cancer (NSCLC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures ‑ Streamlined Authority Code 11468
                                                                                                                Continuing combination treatment (with ipilimumab) of first‑line drug therapy
                                                                                                                The condition must be squamous type non‑small cell lung cancer (NSCLC); AND
                                                                                                                Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND
                                                                                                                Patient must not have developed disease progression while receiving PBS‑subsidised treatment with this drug for this condition; AND
                                                                                                                The treatment must not exceed 24 months in total, measured from the initial dose, or, must not extend beyond disease